Rising prevalence of diabetes in price sensitive markets of India and China to be the driving force behind increased sales of biosimilar insulin, says RNCOS.
(prHWY.com) February 25, 2013 - NOIDA, India -- According to a new research report by RNCOS entitled, "Global Biosimilars Market Forecast to 2015", biosimilar insulins have a very promising market in the future as the rising incidences of diabetes would require more affordable biosimilar insulins. Both the US and Europe are expected to show a promising growth, but especially significant growth will be exhibited in the developing countries, such as China and India which have the highest diabetes prevalence in the world. These geographies are rapidly adopting the technological advancements related to insulin that are expected to govern maximum growth in this segment. Moreover, patents on some of the rapid-acting or regular insulin analogs have already expired in the US and Europe, with several patent expiries lined up post-2012. Eli Lilly's Humalog (Insulin Lispro) is expected to be the first drug to face biosimilar competition in 2013.
Besides, our research has found that although being at a nascent stage, the global biosimilar industry holds a huge potential. A number of patent expiries of key biologics and alarmingly rising healthcare and biologic costs across the world are the prime factors triggering the growth of biosimilars. As biosimilars target specific diseases as efficiently as the branded counterparts at a much lesser price, their market seems to hold a much larger pie in the market. The second-generation biosimilars also seems to hold huge potential and is expected to open up new avenues of growth in the global Biosimilars Industry.
The report, by RNCOS, spread in around 140 pages provides an extensive research and in-depth analysis of the current size and future outlook of the Global Biosimilars Market. It provides market analysis of the Biosimilars Industry along with key market segments and geographical segmentation. Various types of biosimilars, such as erythropoietin, human growth hormone, G-CSF, monoclonal antibody, human insulin, and interferons have been analyzed comprehensively in the report. The Biosimilars Industry is quiet diverse in terms of regulated and unregulated markets. Some of the key geographies in this diverse market have been analyzed while compiling the report. A detailed competitive evaluation provides the reader with a comprehensive analysis on the latest industry activities. Overall, the report provides a holistic understanding of the global Biosimilars Industry and its promising future to the reader.
For FREE SAMPLE of this report visit:
http://www.rncos.com/Report/IM379.htm
Some of our Related Reports are:
- Global Biotech API Market Analysis (
http://www.rncos.com/Report/IM424.htm)
- EPO Biosimilars Market Forecast to 2015 (
http://www.rncos.com/Report/IM392.htm)
- G-CSF Biosimilars Market Forecast to 2015 (
http://www.rncos.com/Report/IM393.htm)
- HGH Biosimilars Market Forecast to 2015 (
http://www.rncos.com/Report/IM394.htm)
- Global Protein Therapeutics Market Forecast to 2015 (
http://www.rncos.com/Report/IM389.htm)
Check Related REPORTS on:
http://www.rncos.com/Healthcare_Industry.htm
About RNCOS
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.
###